Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial - Haass, M; Kitzman, D W; Anand, I S (Circ Heart Fail, 2011)
et al.